Komori Toshihiko
Chugai Pharmaceutical Co Ltd, 1-9 Kyobashi 2-Chome, Chuo-Ku, Tokyo 104-8301, Japan.
Curr Opin Investig Drugs. 2004 Mar;5(3):334-8.
CETi-1, a vaccine that stimulates antibodies specific for cholesteryl ester transfer protein, is under development by AVANT Immunotherapeutics for potential use in reducing risk factors for atherosclerosis. Phase II trials with CETi-1 in hypercholesterolemia and atherosclerosis had been initiated by August 2001.
CETi-1是一种能刺激针对胆固醇酯转运蛋白的特异性抗体的疫苗,目前正由AVANT免疫治疗公司进行研发,有望用于降低动脉粥样硬化的风险因素。截至2001年8月,已启动了CETi-1针对高胆固醇血症和动脉粥样硬化的二期试验。